NCT07312526已完成不适用
Shanghai Clinical Cohort - Esophageal Cancer Cohort
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 2,116
- 试验地点
- 1
- 主要终点
- Overal survival
研究概览
简要总结
A prospective cohort of patients who received esophagectomy for esophageal cancer in participating centers.
详细描述
A prospective cohort of patients who received esophagectomy for esophageal cancer in participating centers.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Received esophagectomy in these centers for esophageal cancer.
排除标准
- •No esophagectomy.
结局指标
主要结局
Overal survival
时间窗: From the date of enrollment until the date of death or loss of follow-up, assessed up to 10 years. Follow-up is scheduled every 3 months in the first 2 years. Every 6 months from the 2nd to the 5th year. Then once a year. Until death or loss of follow.
次要结局
未报告次要终点
研究者
Zhigang Li
Prof.
Shanghai Chest Hospital
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
QL1706 Plus Chemotherapy for Borderline Resectable Esophageal CancerEsophageal CancerNCT07283991Ruijin Hospital24
招募中
不适用
Integrated Cf-miRNA and Exosomal miRNA Signature for Early Detection of Esophageal Squamous Cell CarcinomaNCT07266363City of Hope Medical Center600
尚未招募
不适用
Prospective Multicenter Observational Study of Esophageal Preservation Survival in definitive Chemoradiotherapy +/- Photodynamic Therapy for Esophageal CancerEsophageal CancerJPRN-UMIN000043767agoya University150
招募中
2 期
A Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults with Active Eosinophilic Esophagitis (The "EvolvE" Study)Eosinophilic Esophagitis2024-512767-30-00Celldex Therapeutics Inc.23
招募中
3 期
Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy - The Phase II/III RAMIRIS STUDY2024-512934-14-00Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH319